The Imbalanced Expression of Matrix Metalloproteinases in Nephrogenic Systemic Fibrosis PDF Print E-mail
Monday, 16 August 2010 10:23
Brent C. Kelly, MD, Leslie Scroggins Markle, MD, Jennifer L. Vickers, MD, Matthew S. Petitt, DO, Sharon S. Raimer, MD, and Catherine McNeese, MD

Background:
Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-b has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express a-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis.

Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples.

Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and a-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison.

Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for a-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin.

Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques.

Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation. ( J Am Acad Dermatol 2010;63:483-9.)

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?

Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;Pulmonary arterial...

» Adult Stem Cells Are Helping Scleroderma Patients

Dr. Richard Burt and colleagues at Northwestern University have just published a new study in that provides more evidence for the success of adult stem cell transplant in treating System Sclerosis ().Ten patients were treated with their own adult...

» Long-Term Outcomes of Scleroderma Renal Crisis

In a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» New Hope for Patients

Pulmonary Fibrosis (PF) and (PAH) are incurable rare lung diseases and are the leading cause of mortality in patients with Systemic Sclerosis (SSc). However patients might have a reason to breathe easier since researchers from the University of...

» Lymph Drainage Massage May Help Edema in Systemic Sclerosis

A special massage technique designed to increase lymphatic system circulation, remove excess , and improve vascular tone may offer patients with systemic sclerosis (SSc) some relief from . A pilot study of the method was reported by Susanna Maddali...